Prove its efficacy and safety first


(FILES) In this file photo taken on October 17, 2018, a marijuana plant is pictured in Vancouver, Canada. - Canadian cannabis producer Aphria on Friday, December 28, 2018 rejected a proposed Can2.8 billion (2.1 billion US) takeover bid by US-based Xanthic Biopharma, calling it hostile and under-valued. Green Growth Brands, a division of Xanthic Biopharma, presented a conditional offer of Can11 per share on December 27, 2018 after markets closed. (Photo by Don MacKinnon / AFP)

THE Star Online last week reported the Deputy Health Minister of Malaysia’s response to Thailand approving marijuana for medical use and research (tinyurl.com/star-cannabis). Marijuana is also known as cannabis, or ganja in Malay.

Accor­ding to Deputy Minister Dr Lee Boon Chye, pharmaceutical firms wishing to register the drug for such use must provide the required standard information on its quality, efficacy and safety.

The Star Christmas Special Promo: Save 35% OFF Yearly. T&C applies.

Monthly Plan

RM 13.90/month

Best Value

Annual Plan

RM 12.33/month

RM 8.02/month

Billed as RM 96.20 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Letters

'Dr' title no trivial matter: MMC must uphold professional standards
Difficult SPM paper needs careful assessment before marking
Older – but also wiser, kinder and more hopeful in 2026
Isn’t healthcare a basic right of every Malaysian?
Solve e-hailing chaos ahead of VM2026
An attack on one innocent is an attack on all of humanity
Ecoanxiety: The overlooked toll of the climate crisis
From victims to vigilance: Building scam resistance among young Malaysians
Incestuous crimes: A failure of the family’s protective structure
We need a results-oriented approach to sports

Others Also Read